ライフサイエンスコーパス: maximum tolerated dose

1 hase, an expansion cohort was treated at the maximum tolerated dose.

2 identify dose-limiting toxic effects and the maximum tolerated dose.

3 e used a standard 3+3 design to identify the maximum tolerated dose.

4 was started with dosing every 2 weeks at the maximum tolerated dose.

5 rmacokinetic properties and a relatively low maximum tolerated dose.

6 300 mg/day was established as the maximum tolerated dose.

7 to 400 mg in a 21-day cycle to establish the maximum tolerated dose.

8 lity profile of MDV3100 and to establish the maximum tolerated dose.

9 ncentrations of NAC that were well below the maximum tolerated dose.

10 re to determine the safety, feasibility, and maximum tolerated dose.

11 s well tolerated without identification of a maximum tolerated dose.

12 y, which was escalated to each participant's maximum tolerated dose.

13 ry endpoints were dose-limiting toxicity and maximum tolerated dose.

14 disease benefit most from treatment with the maximum-tolerated dose.

15 Dose escalation to 480 mg did not identify a maximum-tolerated dose.

16 were multiple doses up to 10 mg/kg without a maximum-tolerated dose.

17 , 19 additional patients were treated at the maximum-tolerated dose.

18 g in 0.3 mug/kg per day being determined the maximum-tolerated dose.

19 olerable when administered at the respective maximum tolerated doses.

20 Of the 18 patients given the maximum tolerated dose, 11 (61%) achieved an objective (

21 7) was given continuous oral olaparib at the maximum tolerated dose (400 mg twice daily), and the sec

22 jection time (mean increase from baseline at maximum tolerated dose, 85 [SD 5] ms), the most sensitiv

23 Cyclophosphamide administered at a maximum tolerated dose activated a transient, weak innat

24 ty of rovalpituzumab tesirine, including the maximum tolerated dose and dose-limiting toxic effects.

25 The primary endpoints were maximum tolerated dose and dose-limiting toxicity for ph

26 ections, respectively, were to establish the maximum tolerated dose and dose-limiting toxicity of bev

27 We aimed to establish the maximum tolerated dose and establish the recommended pha

28 A maximum tolerated dose and initial signal of efficacy in

29 The primary objective was to determine the maximum tolerated dose and recommended dose of panobinos

30 bel, dose-escalation design to determine the maximum tolerated dose and recommended phase 2 dose (RP2

31 We aimed to define the maximum tolerated dose and recommended phase 2 dose of t

32 The primary objectives were to establish the maximum tolerated dose and recommended phase 2 dose of v

33 Primary objectives were to determine the maximum tolerated dose and the recommended dose for futu

34 The main goal was to define the maximum tolerated dose and to assess safety and efficacy

35 ble plexiform neurofibromas to determine the maximum tolerated dose and to evaluate plasma pharmacoki

36 ndary objectives included determination of a maximum-tolerated dose and assessment of clinical activi

37 e conducted a phase I study to determine the maximum-tolerated dose and pharmacokinetics of vorinosta

38 ssess safety and tolerability, determine the maximum tolerated dose, and identify the recommended pha

39 ts, but PT-RAIT, at approximately 30% of its maximum tolerated dose, and radioimmunotherapy alone, at

40 The primary endpoint in phase 1 was the maximum tolerated dose, and the primary endpoint in phas

41 Phase I and II studies show that the maximum tolerated dose, and thus the recommended dose fo

42 assess the safety profile, to determine the maximum tolerated dose, and to establish the recommended

43 article formulation increased the half-life, maximum tolerated dose, and tumor accumulation of doxoru

44 d-ISF35 viral particles (vp), with a defined maximum tolerated dose as 1 x 10(11) vp.

45 c tumor xenografts revealed that traditional maximum-tolerated dose chemotherapy, regardless of the a

46 rt 4, 2 x 10(10) vg, n=3 per cohort) and one maximum tolerated dose cohort (cohort 5, 2 x 10(10) vg,

47 Two maximum-tolerated dose combinations were identified: 200

48 es with relatively narrow therapeutic index (maximum tolerated dose/curative dose).

49 Dosing schemas were based on the maximum-tolerated dose derived in a previous phase I stu

50 alation trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities, and ph

51 standard 3 + 3 design was used to determine maximum tolerated dose; dose-limiting toxicities were as

52 The 10-d maximum tolerated dose following a single i.v. injection

53 The primary endpoints were maximum tolerated dose for phase 1, and the rate of very

54 The maximum tolerated dose for sustained treatment (>28 days

55 /kg; one dose every 21 days) to identify the maximum tolerated dose for the phase 2 study.

56 During the dose-escalation phase, the maximum-tolerated dose for bendamustine was not reached;

57 ion of the route of injection as well as the maximum-tolerated dose for immunodeficient strains.

58 nts in separate cohorts experienced UHT; the maximum-tolerated dose for this regimen was not reached.

59 The primary objective (to determine the maximum tolerated dose) has been reported previously.

60 n three parts: dose escalation to define the maximum tolerated dose; identification of the recommende

61 tumumab administered once every 14 days, the maximum-tolerated dose identified in adults.

62 agent and in combination with rituximab; the maximum tolerated dose in CLL was 1.0 mg/kg as a result

63 The maximum tolerated dose in combination with pegfilgrastim

64 syndrome at 125 mg/m(2) daily x 5, thus the maximum tolerated dose in patients with myelodysplastic

65 In part B, we further investigated the maximum tolerated dose in patients with sporadic platinu

66 avenous (IV) administration of CP-Dox at the maximum tolerated dose increases the infiltration of leu

67 best available therapy (hydroxyurea [at the maximum tolerated dose], interferon or pegylated interfe

68 pletion and CD19 CAR-T cells at or below the maximum tolerated dose (</= 2 x 10(6) CAR-T cells/kg).

69 To determine the maximum tolerated dose (MTD) and dose limiting toxicity

70 The primary objective was to determine the maximum tolerated dose (MTD) and recommended phase 2 dos

71 In 14-day acute toxicity in rats, the maximum tolerated dose (MTD) and the no observed adverse

72 We aimed to identify the maximum tolerated dose (MTD) and the recommended phase 2

73 The aim of this study was to determine the maximum tolerated dose (MTD) and to explore the clinical

74 We conducted a study to estimate the maximum tolerated dose (MTD) of (131)I-anti-CD45 antibod

75 l of this phase I study was to determine the maximum tolerated dose (MTD) of alisertib with irinoteca

76 assess the safety profile and establish the maximum tolerated dose (MTD) of brentuximab vedotin in c

77 hase 1 trial in 34 patients to establish the maximum tolerated dose (MTD) of BV for SR-aGVHD treatmen

78 ients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administere

79 + 3 dose-escalation scheme to determine the maximum tolerated dose (MTD) of carfilzomib.

80 This study aimed to determine the maximum tolerated dose (MTD) of erlotinib in advanced no

81 Phase I study to determine the maximum tolerated dose (MTD) of fluorouracil (FU) in the

82 ; the primary objective was to determine the maximum tolerated dose (MTD) of isatuximab with lenalido

83 We aimed to identify the maximum tolerated dose (MTD) of lenalidomide when combin

84 Finally, the maximum tolerated dose (MTD) of NSC23925b was determined

85 Our aim was to describe the maximum tolerated dose (MTD) of oral OA in patients with

86 phase 1 dose-escalation study determined the maximum tolerated dose (MTD) of oral pomalidomide (4 dos

87 performed a phase 1/2 trial to determine the maximum tolerated dose (MTD) of pomalidomide and to expl

88 te safety and tolerability and determine the maximum tolerated dose (MTD) of single-agent, oral ixazo

89 ated in nano-formulations, which doubled the maximum tolerated dose (MTD) of Taxol.

90 1 was to assess the safety and establish the maximum tolerated dose (MTD) of the combination and phas

91 und that daily subcutaneous injection with a maximum tolerated dose (MTD) of the mGluR2/3 agonist LY3

92 was to evaluate the safety and determine the maximum tolerated dose (MTD) of the regimen.

93 ort, patients received either Nexvax2 at the maximum tolerated dose (MTD) or placebo.

94 mmune-mediated efficacy when compared with a maximum tolerated dose (MTD) regimen in treating platinu

95 ntional chemotherapy drugs administered at a maximum tolerated dose (MTD) remains the backbone for tr

96 The maximum tolerated dose (MTD) was 28 mg/m(2) over 3 hours

97 The maximum tolerated dose (MTD) was defined as 25 mg lenali

98 guanine-DNA alkyltransferase activity, but a maximum tolerated dose (MTD) was not reached.

99 erlap transfusions during dose escalation to maximum tolerated dose (MTD), followed by monthly phlebo

100 When administered at maximum tolerated dose (MTD), hydroxyurea increases feta

101 first-in-human phase 1/2 study assessed the maximum tolerated dose (MTD), pharmacokinetic and pharma

102 ral Z-endoxifen to determine its toxicities, maximum tolerated dose (MTD), pharmacokinetics, and clin

103 ell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD), pharmacokinetics, pharmaco

104 This phase 1 study evaluated maximum tolerated dose (MTD), pharmacokinetics, pharmaco

105 were to determine the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose,

106 targeted agent, was carried out to determine maximum tolerated dose (MTD), safety, pharmacokinetics,

107 th factor receptors (FGFRs) to determine the maximum tolerated dose (MTD), the recommended phase II d

108 Phase 1 established maximum tolerated dose (MTD).

109 nning hydroxyurea therapy and after reaching maximum tolerated dose (MTD).

110 eceived RVDD at 4 dose levels, including the maximum tolerated dose (MTD).

111 ts (PI-naive and PI-exposed patients) at the maximum tolerated dose (MTD).

112 kinetics, we compared them on the basis of a maximum tolerated dose (MTD).

113 d points included dose-limiting toxicity and maximum tolerated dose (MTD).

114 in antagonist, was performed to estimate the maximum-tolerated dose (MTD) and describe dose-limiting

115 Primary aims included estimating the maximum-tolerated dose (MTD) and determining the dose-li

116 We aimed to identify the maximum-tolerated dose (MTD) and dose-limiting toxicity

117 ase I dose escalation study to determine the maximum-tolerated dose (MTD) and dose-limiting toxicity

118 125-mg twice-per-day fed dose was deemed the maximum-tolerated dose (MTD) and RP2D.

119 In this phase I study, the maximum-tolerated dose (MTD) and safety of sunitinib in

120 We undertook this trial to determine the maximum-tolerated dose (MTD) and single-agent activity o

121 ogressive primary CNS tumors to estimate the maximum-tolerated dose (MTD) and to describe the toxicit

122 biologic dose (OBD) as an alternative to the maximum-tolerated dose (MTD) as the primary end point in

123 evaluation of safety, pharmacokinetics, and maximum-tolerated dose (MTD) determination.

124 owder suspension was initiated at 50% of the maximum-tolerated dose (MTD) for the intact tablet.

125 y including dose-expansion cohorts after the maximum-tolerated dose (MTD) has been reached to better

126 intravenously over 2 hours at the pediatric maximum-tolerated dose (MTD) of 52 mg/m(2) daily for 5 c

127 safety, tolerability, pharmacokinetics, and maximum-tolerated dose (MTD) of an oral platelet-derived

128 This phase I study determined the maximum-tolerated dose (MTD) of EC145 administered as a

129 The trial objectives were to identify the maximum-tolerated dose (MTD) of first-line gemcitabine p

130 standard chemotherapy agents, the pediatric maximum-tolerated dose (MTD) of GMTZ in combination with

131 0153933) evaluated safety and determined the maximum-tolerated dose (MTD) of lenalidomide plus bortez

132 and inconvenient, we sought to determine the maximum-tolerated dose (MTD) of oral irinotecan combined

133 This phase Ib study sought to determine the maximum-tolerated dose (MTD) of panobinostat plus bortez

134 stituted a marked departure from the classic maximum-tolerated dose (MTD) strategy, which, given its

135 Buparlisib's maximum-tolerated dose (MTD) was 100 mg/d.

136 The maximum-tolerated dose (MTD) was 18.75 mg/d.

137 ytopenia was dose-limiting at 4.8 mg/kg; the maximum-tolerated dose (MTD) was 3.6 mg/kg.

138 he dose-limiting toxicity (DLT) for CLL, the maximum-tolerated dose (MTD) was 75 mg/m(2), and the mos

139 Dose escalation proceeded until either the maximum-tolerated dose (MTD) was achieved or, in the abs

140 nned dose was reached in all trials, but the maximum-tolerated dose (MTD) was defined in only 13 stud

141 The maximum-tolerated dose (MTD) was determined to be 25 mg

142 The maximum-tolerated dose (MTD) with dose-escalated hypofra

143 the safety, dose-limiting toxicities (DLT), maximum-tolerated dose (MTD), and pharmacokinetics of im

144 termine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD), as well as to provide phar

145 e purpose of this study was to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (

146 ith refractory solid tumors to determine its maximum-tolerated dose (MTD), pharmacokinetics, and modu

147 This phase I study evaluated the maximum-tolerated dose (MTD), pharmacokinetics, and phar

148 Dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), pharmacokinetics, immunoge

149 We determine the maximum-tolerated dose (MTD), pharmacokinetics, safety,

150 The primary end points were establishing the maximum-tolerated dose (MTD), recommended phase II dose

151 PURPOSE To evaluate the maximum-tolerated dose (MTD), safety profile, and immuno

152 results of a phase I trial to determine the maximum-tolerated dose (MTD), safety profile, and pharma

153 This was a phase I study to determine the maximum-tolerated dose (MTD), safety, and preliminary ef

154 this first-in-human trial were to determine maximum-tolerated dose (MTD), safety, dose-limiting toxi

155 erformed a phase I/II study to determine the maximum-tolerated dose (MTD), safety, efficacy, and phar

156 -in-human dose-escalation study assessed the maximum-tolerated dose (MTD), safety, pharmacokinetics,

157 phase I, dose-escalation study assessed the maximum-tolerated dose (MTD), safety, pharmacokinetics,

158 ase I dose-escalation study investigated the maximum-tolerated dose (MTD), safety, preliminary activi

159 of this phase I trial were to determine the maximum-tolerated dose (MTD), toxicity profile, dose-lim

160 del to guide dose escalation to identify the maximum-tolerated dose (MTD).

161 formulation was subsequently studied at the maximum-tolerated dose (MTD).

162 cells, and tumor biopsies in patients at the maximum-tolerated dose (MTD).

163 Additional patients were enrolled at the maximum-tolerated dose (MTD).

164 -RAIT of 18.5 MBq ( approximately 50% of its maximum tolerated dose [MTD]) was as effective as the MT

165 The maximum-tolerated doses (MTDs) were 40 mg/m(2) (schedule

166 een shown to be inferior in identifying true maximum-tolerated doses (MTDs), although the sample size

167 All patients treated at maximum-tolerated dose (n = 25) were evaluable for respo

168 The primary objective was to identify the maximum tolerated dose of (90)Y-DOTA-epratuzumab.

169 2008, and June 4, 2009, and had received the maximum tolerated dose of 15 mg lenalidomide; and 40 wer

170 c activity demonstrable at 3 microg/kg and a maximum tolerated dose of 30 microg/kg.

171 3) was given continuous oral olaparib at the maximum tolerated dose of 400 mg twice daily, and the se

172 At a maximum tolerated dose of 7.5 mg/kg, tumor cells in vivo

173 In a phase I study, the maximum tolerated dose of AZD1775 in combination with ca

174 The maximum tolerated dose of brentuximab vedotin when combi

175 The primary objective was to establish the maximum tolerated dose of CPI-613 (as assessed by dose-l

176 The maximum tolerated dose of CPI-613 was 500 mg/m(2).

177 INTERPRETATION: A maximum tolerated dose of CPI-613 was established at 500

178 We aimed to establish the maximum tolerated dose of CPI-613 when used in combinati

179 ssing wild-type CTR1 was reduced by a single maximum tolerated dose of DDP in vivo, whereas the CTR1(

180 The maximum tolerated dose of EC0905 in dogs was 0.25 mg/kg

181 1 portion of this study was to establish the maximum tolerated dose of everolimus that could be combi

182 In vivo, using the maximum tolerated dose of gossypol for sequential daily

183 The maximum tolerated dose of interleukin-2 was 1x10(6) IU p

184 dose-finding methodology for estimating the maximum tolerated dose of investigational anticancer age

185 The maximum tolerated dose of ixazomib was established as 2.

186 rded no dose-limiting toxic effects, and the maximum tolerated dose of lenalidomide in combination wi

187 ive of these two trials was to determine the maximum tolerated dose of lenalidomide in combination wi

188 We aimed to determine the maximum tolerated dose of lenalidomide, an oral immunomo

189 e primary study endpoint was to identify the maximum tolerated dose of lenalidomide.

190 By contrast, the maximum tolerated dose of liposomal alendronic acid was

191 Our aim was to establish the maximum tolerated dose of no-carrier-added (NCA) (131)I-

192 The maximum tolerated dose of omecamtiv mecarbil was 0.5 mg/

193 The conjugates increased the maximum tolerated dose of paclitaxel by up to 100-fold f

194 neous weekly bortezomib, and determining the maximum tolerated dose of panobinostat in this regimen.

195 lling six escalation design to determine the maximum tolerated dose of panobinostat, and allocated pa

196 outcomes were dose-limiting toxicities, the maximum tolerated dose of ricolinostat in this combinati

197 The maximum tolerated dose of rovalpituzumab tesirine was 0.

198 Subjects self-administered the maximum tolerated dose of RW-SAIL (n = 218) or placebo (

199 In the phase 1 part, the maximum tolerated dose of the combination was not reache

200 mary end point was the identification of the maximum tolerated dose of the combination.

201 In vivo studies in mice revealed a maximum tolerated dose of TIR-199 at 25 mg/kg.

202 The maximum tolerated dose of TMZ was 100 mg/m(2).

203 TMZ, providing a substantial increase in the maximum tolerated dose of TMZ.

204 The primary phase I end point was the maximum tolerated dose of TMZ.

205 3] and wound infection [grade 3]); thus, the maximum tolerated dose of TPCS2a was 1.0 mg/kg.

206 INTERPRETATION: The maximum tolerated dose of trastuzumab deruxtecan was not

207 l (HbA1c 7.1-11.0% [54-97 mmol/mol]) despite maximum tolerated doses of metformin alone or with a sul

208 The goal was to determine the maximum-tolerated dose of (131)I-MIBG in two consecutive

209 that showed T-DM1 was well tolerated at the maximum-tolerated dose of 3.6 mg/kg every 3 weeks, with

210 xpansion cohort at the previously determined maximum-tolerated dose of 960 mg orally twice a day.

211 pilot phase I trial evaluated the safety and maximum-tolerated dose of p53 gene transfer using an ade

212 , and abolished attrition produced by a near maximum-tolerated dose of PTX.

213 e event profile, dose-limiting toxicity, and maximum-tolerated dose of recombinant human IL-15 (rhIL-

214 treated at 960 mg twice a day, which is the maximum-tolerated dose of vemurafenib.

215 d the problem of unequal dosing by comparing maximum-tolerated doses of intravenous regimens with pro

216 ed 25 mg twice daily or 100 mg once daily as maximum tolerated doses, on the basis of reversible thro

217 ation with chemotherapy drugs delivered with maximum tolerated dose or metronomic scheduling.

218 ability of emactuzumab, and to determine the maximum tolerated dose or optimal biological dose.

219 ts included identification of safety and the maximum tolerated dose or recommended phase 2 dosing and

220 ing a standard 3 + 3 design to establish the maximum tolerated dose, patients received either 1 x 10(

221 We investigated the safety, tolerability, maximum tolerated dose, pharmacokinetic and pharmacodyna

222 termine the dose-limiting toxicities (DLTs), maximum tolerated dose, pharmacokinetic profile, and res

223 Study endpoints were safety, maximum tolerated dose, pharmacokinetic profile, pharmac

224 Safety, maximum-tolerated dose, pharmacokinetics (PKs), pharmaco

225 ere increased to 300 mg twice daily, with no maximum tolerated dose recorded.

226 We aimed to define feasibility, toxicity, maximum tolerated dose, response rate, and biological co

227 This phase 1/2 trial evaluated the maximum tolerated doses, safety, and efficacy of pomalid

228 administration scheme with a more classical maximum tolerated dose schedule.

229 rocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL choles

230 Maximum tolerated dose studies have demonstrated safety

231 armacokinetics/pharmacodynamics studies, and maximum-tolerated-dose studies of micafungin that examin

232 They participated in a modified maximum tolerated dose study of intranasal oxytocin (Syn

233 del, CP nanoparticles have a fourfold higher maximum tolerated dose than free drug, and induce nearly

234 gel containing PNC (PNC-gel) showed a lower maximum tolerated dose than PPT-containing gel (PPT-gel)

235 -Dox nanoassemblies showed a fivefold higher maximum-tolerated dose than the free drug, and moreover,

236 A maximum tolerated dose (the highest dose associated with

237 were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with

238 The primary aim was to establish maximum tolerated dose (the highest infusion rate tolera

239 For the 18 patients given the maximum tolerated dose, the most common grade 3-4 non-ha

240 Although we did not identify a maximum tolerated dose, there was more gastro-intestinal

241 The primary endpoint was to estimate the maximum tolerated dose, to define the toxic effects of c

242 s-has been shown to be more efficacious than maximum tolerated dose treatment in preclinical studies,

243 lated during phases 1 and 2, with individual maximum tolerated doses used in phase 3.

244 signs of toxicity and a >/=3.5-fold improved maximum tolerated dose versus paclitaxel.

245 The maximum tolerated dose was 1.0 mg because of a case of e

246 The maximum tolerated dose was 1.8 mg per kilogram, administ

247 The maximum tolerated dose was 10(6) CAR T cells per kg, and

248 dian number of treatment cycles given at the maximum tolerated dose was 11 (IQR 4-19).

249 The maximum tolerated dose was 120 muCi of (213)Bi-7.16.4.

250 The maximum tolerated dose was 2.0 mg/m(2), which 40 patient

251 The maximum tolerated dose was 25 mg per square meter (appro

252 The maximum tolerated dose was 3 mg once daily and the recom

253 follow-up of the 18 patients treated at the maximum tolerated dose was 378 days (IQR 250-602).

254 The maximum tolerated dose was defined as 1 x 10(6) CD19-CAR

255 No maximum tolerated dose was defined.

256 Gilteritinib was well tolerated; the maximum tolerated dose was established as 300 mg/day whe

257 The maximum tolerated dose was established as vemurafenib 96

258 The maximum tolerated dose was exceeded in the cohort receiv

259 The maximum tolerated dose was identified as lenalidomide 25

260 No maximum tolerated dose was identified in part 1.

261 No maximum tolerated dose was identified up to the maximum

262 No maximum tolerated dose was identified.

263 A maximum tolerated dose was not identified.

264 The maximum tolerated dose was not identified; the recommend

265 The maximum tolerated dose was not reached and the recommend

266 The maximum tolerated dose was not reached because of the no

267 The maximum tolerated dose was not reached in patients with

268 dose-limiting toxicity was observed and the maximum tolerated dose was not reached in phase 1 after

269 The maximum tolerated dose was not reached, although full KI

270 ponatremia at the 20 mg dose), therefore the maximum tolerated dose was not reached, and 20 mg was de

271 able toxicity profile up to 20 mg/kg and the maximum tolerated dose was not reached.

272 limiting toxic effects were reported and the maximum tolerated dose was not reached.

273 occurred, at the 20 mg/kg dose, and thus the maximum tolerated dose was not reached.

274 The maximum tolerated dose was not reached.

275 A maximum tolerated dose was not reached.

276 The maximum tolerated dose was not reached.

277 asting 8 weeks) occurred at level 4, but the maximum tolerated dose was not reached.

278 Therefore, the maximum tolerated dose was not reached; the recommended

279 Dose expansion at the maximum tolerated dose was pursued in 15 patients to con

280 No maximum tolerated dose was reached.

281 d not seem to be associated with dose and no maximum tolerated dose was reached.

282 omarker studies were cited subsequently, and maximum tolerated dose was used for subsequent drug deve

283 The maximum-tolerated dose was 101 units/m(2).

284 The maximum-tolerated dose was 200 mg/day, and the dose-limi

285 The maximum-tolerated dose was 680 mg/d, and dose-limiting t

286 The maximum-tolerated dose was defined at 65 mg/m(2) using a

287 Maximum-tolerated dose was not defined.

288 A maximum-tolerated dose was not identified.

289 Maximum-tolerated dose was not reached, because full dos

290 A maximum-tolerated dose was not reached.

291 No dose-limiting toxicities occurred, and a maximum-tolerated dose was not reached.

292 r dose-limiting toxicities were noted, and a maximum-tolerated dose was not reached.

293 The maximum-tolerated dose was not reached.

294 A maximum-tolerated dose was not reached.

295 gue) and 10 mg/d (hyperglycemia); hence, the maximum-tolerated dose was not reached.

296 Maximum tolerated doses were 400 and 3,000 ppm for CP-31

297 ring drugs, including a diuretic, at full or maximum tolerated doses were randomly assigned to 14 wee

298 The maximum-tolerated doses were defined as 125 mg/m(2)/d fo

299 d dose, and radioimmunotherapy alone, at its maximum tolerated dose, were able to arrest growth and e

300 up (RTOG) 0117 determined that 74 Gy was the maximum-tolerated dose with concurrent weekly carboplati